Short-term outcomes after the loading phase of intravitreal bevacizumab and subthreshold macular laser in non-center involved diabetic macular edema

AIM: To compare the effectiveness of intravitreal bevacizumab and subthreshold macular photocoagulation (SMP), for the treatment of non-center involved diabetic macular edema (non-CI DME). METHODS: Prospective, randomized, controlled clinical study included patients with type 2 diabetes, non-CI DM...

Full description

Bibliographic Details
Main Authors: Cuervo Lozano, Edgar, González Cortés, Jesús Hernán, Olvera Barrios, Abraham, Treviño Cavazos, Ezequiel, Rodríguez Pedraza, Josué, Mohamed Noriega, Karim, Mohamed Hamsho, Jesús
Format: Article
Language:English
Published: 2018
Online Access:http://eprints.uanl.mx/29854/7/29854.pdf
_version_ 1838551024172793856
author Cuervo Lozano, Edgar
González Cortés, Jesús Hernán
Olvera Barrios, Abraham
Treviño Cavazos, Ezequiel
Rodríguez Pedraza, Josué
Mohamed Noriega, Karim
Mohamed Hamsho, Jesús
author_facet Cuervo Lozano, Edgar
González Cortés, Jesús Hernán
Olvera Barrios, Abraham
Treviño Cavazos, Ezequiel
Rodríguez Pedraza, Josué
Mohamed Noriega, Karim
Mohamed Hamsho, Jesús
author_sort Cuervo Lozano, Edgar
collection Repositorio Institucional
description AIM: To compare the effectiveness of intravitreal bevacizumab and subthreshold macular photocoagulation (SMP), for the treatment of non-center involved diabetic macular edema (non-CI DME). METHODS: Prospective, randomized, controlled clinical study included patients with type 2 diabetes, non-CI DME and best-corrected visual acuity (BCVA) of 0.30 logMAR or better. Each eye was randomized into three groups: group 1, monthly intravitreal bevacizumab; group 2, single SMP; group 3, single SMP and monthly bevacizumab. Main outcome measures were BCVA, and macular thickness measured with optical coherence tomography as macular central subfield thickness (CST), macular area of greater thickness (MAGT) and total macular volume (TMV). Results were analyzed after 3mo. RESULTS: A total of 32 eyes were included. Group 3 improved in BCVA (0.19±0.16 to 0.12±0.14 logMAR; P=0.041) and in TMV (7.90±0.57 to 7.65±0.73 mm3 ; P=0.025). Group 1 improved in MAGT (325±26.26 to 298.20±44.85 μm; P=0.022) and TMV (7.79±0.57 to 7.50±0.56 mm3, P=0.047). Group 2 didn’t show significant improvement of any variable. CONCLUSION: The loading phase of bevacizumab as monotherapy or combined with SMP is superior to SMP as monotherapy in providing short-term visual and anatomical improvement in non-CI DME.
format Article
id eprints-29854
institution UANL
language English
publishDate 2018
record_format eprints
spelling eprints-298542025-07-08T16:23:09Z http://eprints.uanl.mx/29854/ Short-term outcomes after the loading phase of intravitreal bevacizumab and subthreshold macular laser in non-center involved diabetic macular edema Cuervo Lozano, Edgar González Cortés, Jesús Hernán Olvera Barrios, Abraham Treviño Cavazos, Ezequiel Rodríguez Pedraza, Josué Mohamed Noriega, Karim Mohamed Hamsho, Jesús AIM: To compare the effectiveness of intravitreal bevacizumab and subthreshold macular photocoagulation (SMP), for the treatment of non-center involved diabetic macular edema (non-CI DME). METHODS: Prospective, randomized, controlled clinical study included patients with type 2 diabetes, non-CI DME and best-corrected visual acuity (BCVA) of 0.30 logMAR or better. Each eye was randomized into three groups: group 1, monthly intravitreal bevacizumab; group 2, single SMP; group 3, single SMP and monthly bevacizumab. Main outcome measures were BCVA, and macular thickness measured with optical coherence tomography as macular central subfield thickness (CST), macular area of greater thickness (MAGT) and total macular volume (TMV). Results were analyzed after 3mo. RESULTS: A total of 32 eyes were included. Group 3 improved in BCVA (0.19±0.16 to 0.12±0.14 logMAR; P=0.041) and in TMV (7.90±0.57 to 7.65±0.73 mm3 ; P=0.025). Group 1 improved in MAGT (325±26.26 to 298.20±44.85 μm; P=0.022) and TMV (7.79±0.57 to 7.50±0.56 mm3, P=0.047). Group 2 didn’t show significant improvement of any variable. CONCLUSION: The loading phase of bevacizumab as monotherapy or combined with SMP is superior to SMP as monotherapy in providing short-term visual and anatomical improvement in non-CI DME. 2018 Article PeerReviewed text en cc_by_nc_nd http://eprints.uanl.mx/29854/7/29854.pdf http://eprints.uanl.mx/29854/7.haspreviewThumbnailVersion/29854.pdf Cuervo Lozano, Edgar y González Cortés, Jesús Hernán y Olvera Barrios, Abraham y Treviño Cavazos, Ezequiel y Rodríguez Pedraza, Josué y Mohamed Noriega, Karim y Mohamed Hamsho, Jesús (2018) Short-term outcomes after the loading phase of intravitreal bevacizumab and subthreshold macular laser in non-center involved diabetic macular edema. International Journal of Ophthalmology, 11 (6). pp. 981-985. ISSN 2222-3959 doi:10.18240/ijo.2018.06.14
spellingShingle Cuervo Lozano, Edgar
González Cortés, Jesús Hernán
Olvera Barrios, Abraham
Treviño Cavazos, Ezequiel
Rodríguez Pedraza, Josué
Mohamed Noriega, Karim
Mohamed Hamsho, Jesús
Short-term outcomes after the loading phase of intravitreal bevacizumab and subthreshold macular laser in non-center involved diabetic macular edema
thumbnail https://rediab.uanl.mx/themes/sandal5/images/online.png
title Short-term outcomes after the loading phase of intravitreal bevacizumab and subthreshold macular laser in non-center involved diabetic macular edema
title_full Short-term outcomes after the loading phase of intravitreal bevacizumab and subthreshold macular laser in non-center involved diabetic macular edema
title_fullStr Short-term outcomes after the loading phase of intravitreal bevacizumab and subthreshold macular laser in non-center involved diabetic macular edema
title_full_unstemmed Short-term outcomes after the loading phase of intravitreal bevacizumab and subthreshold macular laser in non-center involved diabetic macular edema
title_short Short-term outcomes after the loading phase of intravitreal bevacizumab and subthreshold macular laser in non-center involved diabetic macular edema
title_sort short term outcomes after the loading phase of intravitreal bevacizumab and subthreshold macular laser in non center involved diabetic macular edema
url http://eprints.uanl.mx/29854/7/29854.pdf
work_keys_str_mv AT cuervolozanoedgar shorttermoutcomesaftertheloadingphaseofintravitrealbevacizumabandsubthresholdmacularlaserinnoncenterinvolveddiabeticmacularedema
AT gonzalezcortesjesushernan shorttermoutcomesaftertheloadingphaseofintravitrealbevacizumabandsubthresholdmacularlaserinnoncenterinvolveddiabeticmacularedema
AT olverabarriosabraham shorttermoutcomesaftertheloadingphaseofintravitrealbevacizumabandsubthresholdmacularlaserinnoncenterinvolveddiabeticmacularedema
AT trevinocavazosezequiel shorttermoutcomesaftertheloadingphaseofintravitrealbevacizumabandsubthresholdmacularlaserinnoncenterinvolveddiabeticmacularedema
AT rodriguezpedrazajosue shorttermoutcomesaftertheloadingphaseofintravitrealbevacizumabandsubthresholdmacularlaserinnoncenterinvolveddiabeticmacularedema
AT mohamednoriegakarim shorttermoutcomesaftertheloadingphaseofintravitrealbevacizumabandsubthresholdmacularlaserinnoncenterinvolveddiabeticmacularedema
AT mohamedhamshojesus shorttermoutcomesaftertheloadingphaseofintravitrealbevacizumabandsubthresholdmacularlaserinnoncenterinvolveddiabeticmacularedema